Ovid Therapeutics Inc (OVID)
0.75
+0.02
(+3.25%)
USD |
NASDAQ |
Jun 28, 16:00
0.7566
+0.01
(+0.88%)
After-Hours: 20:00
Ovid Therapeutics Enterprise Value: -37.05M for June 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 28, 2024 | -37.05M |
| June 27, 2024 | -38.72M |
| June 26, 2024 | -39.70M |
| June 25, 2024 | -40.60M |
| June 24, 2024 | -34.21M |
| June 21, 2024 | -34.92M |
| June 20, 2024 | -40.53M |
| June 18, 2024 | -34.36M |
| June 17, 2024 | -34.24M |
| June 14, 2024 | 143.15M |
| June 13, 2024 | 136.76M |
| June 12, 2024 | 136.76M |
| June 11, 2024 | 130.38M |
| June 10, 2024 | 129.67M |
| June 07, 2024 | 119.74M |
| June 06, 2024 | 129.67M |
| June 05, 2024 | 128.25M |
| June 04, 2024 | 121.87M |
| June 03, 2024 | 123.99M |
| May 31, 2024 | 126.83M |
| May 30, 2024 | 126.83M |
| May 29, 2024 | 122.57M |
| May 28, 2024 | 126.12M |
| May 24, 2024 | 122.57M |
| May 23, 2024 | 123.28M |
| Date | Value |
|---|---|
| May 22, 2024 | 138.89M |
| May 21, 2024 | 130.38M |
| May 20, 2024 | 132.51M |
| May 17, 2024 | 133.22M |
| May 16, 2024 | 142.08M |
| May 15, 2024 | 145.28M |
| May 14, 2024 | 138.89M |
| May 13, 2024 | 123.99M |
| May 10, 2024 | 122.57M |
| May 09, 2024 | 125.71M |
| May 08, 2024 | 128.55M |
| May 07, 2024 | 122.17M |
| May 06, 2024 | 123.59M |
| May 03, 2024 | 126.42M |
| May 02, 2024 | 127.13M |
| May 01, 2024 | 126.42M |
| April 30, 2024 | 125.71M |
| April 29, 2024 | 146.25M |
| April 26, 2024 | 129.25M |
| April 25, 2024 | 121.46M |
| April 24, 2024 | 132.79M |
| April 23, 2024 | 136.34M |
| April 22, 2024 | 132.79M |
| April 19, 2024 | 138.46M |
| April 18, 2024 | 137.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-47.66M
Minimum
May 31 2022
429.11M
Maximum
Aug 19 2020
99.76M
Average
80.02M
Median
Enterprise Value Benchmarks
| Innoviva Inc | 1.292B |
| Ligand Pharmaceuticals Inc | 1.199B |
| Intra-Cellular Therapies Inc | 6.753B |
| Marinus Pharmaceuticals Inc | 24.49M |
| Arcutis Biotherapeutics Inc | 874.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.69M |
| Revenue (Quarterly) | 0.148M |
| Total Expenses (Quarterly) | 17.56M |
| EPS Diluted (Quarterly) | -0.17 |
| Profit Margin (Quarterly) | -7.90K% |
| Earnings Yield | -97.33% |
| Normalized Earnings Yield | -97.33 |